Linked Life Data

19546410

Source:http://linkedlifedata.com/resource/pubmed/id/19546410

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-6-23
pubmed:abstractText
Treatment of anemia in chronic kidney disease (CKD) with erythropoietin-stimulating agents (ESAs) is commonplace. The optimal hemoglobin treatment target has not been established. A clearer understanding of the health-related quality of life (HQOL) impact of hemoglobin target levels is needed. We systematically reviewed the randomized controlled trial (RCT) data on HQOL for patients treated with low to intermediate (9.0-12.0 g/dL) and high hemoglobin target levels (>12.0 g/dL) and performed a meta-analysis of all available 36-item short-form (SF-36) RCT data.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1538-3679
pubmed:author
pubmed:issnType
Electronic
pubmed:day
22
pubmed:volume
169
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1104-12
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis.
pubmed:affiliation
Departments of Community Health Sciences and Medicine, Centre for Health and Policy Studies, University of Calgary, Calgary, Alberta,Canada.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Meta-Analysis